not tagged
not tagged
['breast']
dana-farber's chris labaki, md ( ), details how real-world progression-free survival and time to next line of therapy may be useful intermediate endpoints for survival in patients with advanced breast cancer. research presented at #asco22 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090